Locally-Hosted AI for Uncompromising Drug Discovery
An isolated, on-premise Large Language Model engineered to ingest, parse, and synthesise dense pharmacological literature and complex biostatistics with zero data leakage.
Predictive Biostatistics
Beyond literature synthesis, SynapTx™ provides robust computational support for complex biostatistics and predictive biopharmaceutics. The engine assists in powering clinical trial designs, mapping multi-variable PK/PD relationships, and analysing critical datasets to mathematically de-risk early-phase formulation strategies before bench execution.
High-Throughput Literature Parsing & Target Identification
Drug development programmes are frequently bottlenecked by the sheer volume of unstructured medical data. SynapTx™ operates as a sovereign, localised large language model, capable of instantly synthesising thousands of peer-reviewed journals and clinical registries within a completely air-gapped environment.
- Extracts hidden pharmacokinetic relationships and novel target opportunities that manual human analysis inherently misses.
- Generates actionable, heavily referenced outputs designed specifically to guide biostatisticians and formulation scientists.
- Guarantees absolute IP sovereignty, allowing sponsors to process highly proprietary molecular assets with zero risk of public cloud exposure.
Multi-Dimensional Pathophysiology Mapping
The true bottleneck in modern drug discovery is not a lack of data, but the inability to synthesise it. SynapTx™ operates as an unparalleled bioinformatics engine, parsing decades of dense, peer-reviewed literature and complex pathophysiology queries in seconds. By identifying non-obvious correlations between disease states and molecular pathways, the AI highlights novel target opportunities that traditional manual analysis would miss. This enables sponsors to initiate development programmes with a heavily referenced, scientifically rigorous foundation.
Predictive Pharmacokinetics & In Vivo Anticipation
A molecule’s success relies on absolute biopharmaceutical viability. Utilising its dedicated biostatistical architecture, SynapTx™ runs advanced predictive modelling to anticipate critical ADMET profiles before bench formulation begins. By mapping complex pharmacokinetic and pharmacodynamic (PK/PD) relationships, the platform allows our formulation scientists to engineer around severe solubility or bioavailability limitations early, definitively de-risking the pathway to clinical trials.
Embedded CMC Strategy & Scale-Up
SynapTx™ does not exist in a vacuum; it is the computational brain powering Dhee Lifesciences' end-to-end development. The insights generated by our local large language model directly inform our Chemistry, Manufacturing, and Controls (CMC) strategy. By computationally optimising the formulation parameters early, we guarantee a seamless technology transfer from bench to commercial manufacturing with stringent, ICH-compliant oversight.